Cisplatin resistance of NSCLC cells involves upregulation of visfatin through activation of its transcription and stabilization of mRNA

Radiation exposure triggers the malignancy of non‑small cell lung cancer cells through the activation of visfatin/Snail signaling

(2021) Liang Xiao et al.   ONCOLOGY REPORTS

LncRNA MALAT1 Regulates the Cell Proliferation and Cisplatin Resistance in Gastric Cancer via PI3K/AKT Pathway

(2020) Qingqiang Dai et al.   Cancer Management and Research

NAMPT regulates PKM2 nuclear location through 14‐3‐3ζ: Conferring resistance to tamoxifen in breast cancer

(2019) Xin Ge et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis

(2019) Tsung-Chieh Lin   Cancer Management and Research

Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin

(2019) Zahra Bolandghamat Pour et al.   BMC CANCER

The Correlation of Visfatin and Its Gene Polymorphism with Non-Small Cell Lung Cancer

(2018) Li-Juan Zhang et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

(2018) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer

(2017) Misako Nagasaka et al.   Expert Review of Anticancer Therapy

Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

(2017) James D McKay et al.   NATURE GENETICS

Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases

(2016) Guanghai Wang et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Molecular mechanisms of synergistic induction of apoptosis by the combination therapy with hyperthermia and cisplatin in prostate cancer cells

(2016) Jian-fu Zhang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin

(2016) Wenxia Hu et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Dysregulation of TTP and HuR plays an important role in cancers

(2016) Hao Wang et al.   TUMOR BIOLOGY

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2

(2015) Tingting Liu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Clinical Trials Integrating Immunotherapy and Radiation for Non–Small-Cell Lung Cancer

(2015) Megan E. Daly et al.   Journal of Thoracic Oncology

RNA-stabilizing proteins as molecular targets in cardiovascular pathologies

(2015) Sahana Suresh Babu et al.   TRENDS IN CARDIOVASCULAR MEDICINE

Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach

(2014) F. Rotolo et al.   ANNALS OF ONCOLOGY

STAT3, a key regulator of cell-to-cell communication in the heart

(2014) Arash Haghikia et al.   CARDIOVASCULAR RESEARCH

Systems biology of cisplatin resistance: past, present and future

(2014) L Galluzzi et al.   Cell Death & Disease

Nampt/PBEF/visfatin and cancer

(2010) Tie-qiang Bi et al.   CANCER BIOLOGY & THERAPY

Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study

(2008) Ravi Retnakaran et al.   CLINICAL ENDOCRINOLOGY